Physician profile
Joseph L Meyer
NPI 1609878339
$3,556.79
in general payments reported to CMS, 2019-2025
27 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $475 · 2021: $255 · 2022: $838 · 2023: $427 · 2024: $353 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561 · Entertainment: $77.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.25 |
| Entertainment | $77.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $617.43 | 2019-2025 | |
| Abbvie INC. | $592.13 | 2022-2025 | |
| Allergan, INC. | $379.08 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $315.98 | 2022-2025 | Vyzulta, Miebo, Lotemax Sm |
| Alcon Vision LLC | $216.61 | 2019-2025 | Clareon, Tryptyr |
| Novartis Pharmaceuticals Corporation | $213.72 | 2019-2023 | |
| Biotissue Holdings INC. | $204.16 | 2023-2025 | |
| Oyster Point Pharma, INC. | $150.88 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $142.59 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $78.67 | 2019-2022 | |
| Optos, INC. | $77.91 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Harrow Eye, LLC | $71.02 | 2024-2025 | Vevye |
| Carl Zeiss Meditec, INC. | $69.33 | 2020 | |
| Thea Pharma INC. | $58.45 | 2022-2025 | Iyuzeh |
| Horizon Therapeutics Plc | $56.07 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $50.47 | 2025 | Oxervate |
| Amgen INC. | $50.25 | 2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $37.76 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $35.52 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $30.72 | 2022 | |
| Rayner Intraocular Lenses Limited | $28.06 | 2023 | Omidria, Rayone Aspheric, Rayone Emv |
| Sight Sciences, INC. | $25.68 | 2025 | Omni Surgical System |
| Shire North American Group INC | $23.30 | 2019 | |
| Aerie Pharmaceuticals, INC. | $17.01 | 2021 | |
| Rxsight INC | $13.99 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.